Strontium-calcium coadministration stimulates bone matrix osteogenic factor expression and new bone formation in a large animal model.
Strontium (Sr) has become increasingly attractive for use in the prevention and treatment of osteoporosis by concomitantly inhibiting bone resorption and enhancing bone formation. Strontium shares similar chemical, physical, and biological characteristics with calcium (Ca), which has been widely used as a dietary supplement in osteoporosis. However, the effects of Sr-Ca coadministration on bone growth and remodeling are yet to be extensively reported. In this study, 18 ovariectomized goats were divided into four groups: three groups of five goats each treated with 100 mg/kg/day Ca, Ca plus 24 mg/kg/day Sr (Ca + 24Sr), or Ca plus 40 mg/kg/day Sr (Ca + 40Sr), and three untreated goats fed low calcium feed. Serum Sr levels increased 6- and 10-fold in the Ca + 24Sr and Ca + 40Sr groups, respectively. Similarly, Sr in the bone increased four- and sixfold in these two groups. Sr-Ca coadministration considerably increased bone mineral apposition rate (MAR). The expression of insulin-like growth factor (IGF)-1 and runt-related transcription factor 2 (Runx2) was significantly upregulated within the Ca + 40Sr treatment group; tumor necrosis factor (TNF)-agr; expression was significantly downregulated in the Ca and Ca + 40Sr groups. The results indicate that Sr-Ca coadministration increases osteogenic gene expression and stimulates new bone formation.
Li
Zhaoyang
Z
Department of Orthopaedics and Traumatology, The University of Hong Kong, Pokfulam, Hong Kong, China.
Lu
William W
WW
Chiu
Peter K Y
PK
Lam
Raymond W M
RW
Xu
Bing
B
Cheung
Kenneth M C
KM
Leong
John C Y
JC
Luk
Keith D K
KD
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects* / Q000502:physiology; D002118:Calcium / Q000097:blood / Q000494:pharmacology*; D050659:Core Binding Factor Alpha 1 Subunit / Q000235:genetics; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006041:Goats; D007334:Insulin-Like Growth Factor I / Q000235:genetics; D007335:Insulin-Like Growth Factor II / Q000235:genetics; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology* / Q000517:prevention & control; D010052:Ovariectomy; D013324:Strontium / Q000097:blood / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D050659:Core Binding Factor Alpha 1 Subunit; D014409:Tumor Necrosis Factor-alpha; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D002118:Calcium; D013324:Strontium